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Abstract
Background: In 2016, the World Health Organization (WHO) adopted a new Global Health Sector Strategy on HIV
for 2016–2021. It establishes 15 ambitious targets, including the ‘90-90-90’ target calling on health systems to
reduce under-diagnosis of HIV, treat a greater number of those diagnosed, and ensure that those being treated
achieve viral suppression.
Discussion: The WHO strategy calls for person-centered chronic care for people living with HIV (PLHIV), implicitly
acknowledging that viral suppression is not the ultimate goal of treatment. However, it stops short of providing an
explicit target for health-related quality of life. It thus fails to take into account the needs of PLHIV who have
achieved viral suppression but still must contend with other intense challenges such as serious non-communicable
diseases, depression, anxiety, financial stress, and experiences of or apprehension about HIV-related discrimination.
We propose adding a ‘fourth 90’ to the testing and treatment target: ensure that 90 % of people with viral load
suppression have good health-related quality of life. The new target would expand the continuum-of-services
paradigm beyond the existing endpoint of viral suppression. Good health-related quality of life for PLHIV entails
attention to two domains: comorbidities and self-perceived quality of life.
Conclusions: Health systems everywhere need to become more integrated and more people-centered to
successfully meet the needs of virally suppressed PLHIV. By doing so, these systems can better meet the needs of
all of their constituents – regardless of HIV status – in an era when many populations worldwide are living much
longer with multiple comorbidities.
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Introduction
In May 2016, in its 69th session, the World Health As-
sembly approved a new Global Health Sector Strategy on
HIV for 2016–2021 [1]. The goal of the strategy is nothing
less than “to end the AIDS epidemic as a public health
threat by 2030” – an incredible advance from some
15 years ago, when the world set out to put three million
people on antiretroviral therapy by the end of 2005.
The strategy, formulated by the World Health
Organization (WHO), establishes 15 ambitious global
targets that are to be achieved by 2020 (Box 1). These
include reducing global HIV-related deaths to below
500,000 annually and fully eliminating mother-to-child
transmission of HIV. Further, the importance of con-
tinuing the quest for a cure for HIV is acknowledged
with an ‘innovation’ target that calls on stakeholders to
“increase research into and development of HIV-related
vaccines and medicines” [1].
Regarding HIV testing and treatment, the strategy puts
forth the ‘90-90-90’ target championed by UNAIDS [2].
This target reflects key points across the continuum of
HIV services, in keeping with the concept that health
systems simultaneously need to reduce under-diagnosis
of HIV, treat a greater number of those diagnosed, and
ensure that those being treated achieve viral suppression.
While reaching the ‘90-90-90’ target would deliver
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tremendous benefits to individuals already infected with
HIV, this target is also important from a public health
perspective since achieving such a large increase in the
number of virally suppressed people would greatly re-
duce onward transmission of the disease.
However, what about the millions of people already
living with HIV? What next following viral suppression?
The WHO strategy alludes to ‘what next’ by defining its
vision as: “zero new HIV infections, zero HIV-related deaths
and zero HIV-related discrimination in a world where
people living with HIV are able to live long and healthy
lives” [1]. Furthermore, the strategy’s central goal, fully ar-
ticulated, is “to end the AIDS epidemic as a public health
threat by 2030, within the context of ensuring healthy lives
and promoting well-being for all at all ages” [1].
A ‘fourth 90’
This broad framing of the undertaking represents a wel-
come change from the more simplistic response to HIV
in the earlier years of the epidemic. However, the strat-
egy does not provide targets for the concept of ensuring
healthy lives and promoting well-being. Thus, we
propose adding a ‘fourth 90’ to the testing and treatment
target: ensure that 90 % of people with viral load sup-
pression have good health-related quality of life (Fig. 1).
We further suggest that good health-related quality of
life for PLHIV entails attention to two domains – co-
morbidities and self-perceived quality of life.
A large body of research has raised questions about
whether PLHIV, as a whole, are at elevated risk for non-
HIV-specific diseases such as kidney disease, cardiovas-
cular disease and various cancers. A careful parsing of
the data on comorbidities in PLHIV indicates that a
higher incidence of some of these diseases is concen-
trated in two subsets of people: those who began taking
antiretroviral therapy during the earliest phase of the
treatment era and those who have experienced more se-
vere immunosuppression, which is a common conse-
quence of late diagnosis [3–6]. Nonetheless, many
questions remain about how to proactively address co-
morbidities in PLHIV, including virally suppressed
PLHIV. As more people taking antiretroviral therapy live
into their fifties, sixties and beyond, healthcare providers
will increasingly be confronted with scenarios in which
multiple diseases need to be managed simultaneously
and multiple types of pharmaceutical interventions need
to be coordinated.
As for self-perceived quality of life, virally suppressed
PLHIV have reported high levels of symptoms such as
fatigue and energy loss, insomnia, sadness and depres-
sion, sexual dysfunction and changes in body appearance
[7]. A cross-sectional study comparing more than 3000
PLHIV with more than 7000 members of the general
population in the United Kingdom reported that health-
Box 1. Draft global health sector strategy on HIV,
2016–2021: global targets for 2020
HIV-related deaths:
 Reduce global HIV-related deaths to below 500,000
 Reduce tuberculosis deaths among people living with HIV
by 75 %
 Reduce hepatitis B and C deaths among people co-infected
with HIV by 10 %, in line with mortality targets for all
people with chronic hepatitis B and C infection
Testing and treatment:
 Ensure that 90 % of people living with HIV know their HIV
status
 Ensure that 90 % of people diagnosed with HIV receive
antiretroviral therapy
 Ensure that 90 % of people living with HIV, and who are on
treatment, achieve viral load suppression
Prevention:
 Reduce new HIV infections to below 500,000
 Zero new infections among infants
Discrimination:
 Zero HIV-related discriminatory laws, regulations and
policies, and zero HIV-related discrimination in all settings,
especially health settings
 Ensure that 90 % of people living with HIV and key
populations report no discrimination in the health sector
Financial sustainability:
 Ensure financial risk protection for 90 % of all people living
with HIV
 Ensure domestic investments in upper middle-income
countries of 95 % of national AIDS resource needs and
annual international HIV investment of US$ 12,700 million
in lower middle-income countries;
 Ensure all countries have integrated essential HIV services
into national health financing arrangements
Innovation:
 Increase research into and development of HIV-related
vaccines and medicines for use in treatment and prevention
 Provision of access by 90 % of countries to integrated health
services covering HIV, tuberculosis, hepatitis B and C,
reproductive health and sexually transmitted infections
Source: [1]
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related quality of life scores were significantly lower
among PLHIV, 75 % of whom were virally suppressed, and
that scores remained significantly lower even when the
analysis was restricted to virally suppressed PLHIV [8].
Addressing these and other related concerns is essential
in order to ensure that the vision of well-being put forth by
the WHO strategy becomes a reality. Indeed, by calling for
person-centered chronic care for PLHIV, the strategy ac-
knowledges that viral suppression is not the ultimate goal
of treatment – that, apart from reducing HIV incidence
and mortality, treatment needs to encompass attention to a
comprehensive set of issues, including non-communicable
diseases (NCDs), mental health disorders, pain manage-
ment and palliative care. Further, the strategy clearly recog-
nizes stigma and discrimination as being detrimental to the
well-being of PLHIV [1].
This is all well and good – and some elements of the
WHO strategy might even be considered visionary in
terms of how they seek to address the needs of PLHIV
beyond viral suppression. Nevertheless, two issues have
not been addressed. One is an explicit target for health-
related quality of life – our proposed ‘fourth 90’. The
other is policy and operational guidance for how to
achieve the ‘fourth 90’. This shortcoming does not re-
flect on WHO, but rather highlights the need for the
global public health community as a whole to develop a
new paradigm for ‘beyond viral suppression’. More pre-
cisely, we need to reconsider the scope of the
continuum-of-services paradigm, which has been an
enormously useful approach to indicate where efforts
should be concentrated in order to prevent fall-off along
the continuum in specific national and sub-national con-
texts. It is now time to add health-related quality of life
of PLHIV to the continuum (Figs. 2 and 3).
We thus call on countries that are already well-
positioned to fully or partially achieve the UNAIDS 90-90-
90 target to lead the way in attending to this matter, and
we ask their national governments to formally commit to
the ‘fourth 90’. This entails establishing a health-related
quality of life target on par with other overarching national
HIV testing and treatment targets, as well as developing
strategies that will guide health systems in their pursuit of
the new target and metrics for tracking their progress.
At first consideration, our proposal may seem relevant
only to those with the luxury of addressing HIV– or, for
that matter, living with HIV and enjoying unhindered ac-
cess to health services – in wealthy countries. After all,
if less than half of PLHIV in some severely resource-
limited countries even have access to antiretroviral ther-
apy, why should the global community worry about the
needs of the virally suppressed populations in high-
income countries? We can think of multiple reasons.
First, controlling HIV infection does not necessarily
eliminate other enormous challenges associated with this
disease. Serious NCDs, depression, anxiety, financial
stress, fear of transmitting HIV to others, uncertainty
about starting a family, and experiences of or apprehen-
sion about HIV-related discrimination – these and a
host of other issues prevent many PLHIV from relegat-
ing their HIV infection to the periphery of daily life. In
the coming years, healthcare models developed in high-
income countries in response to these issues will directly
inform how health systems in low- and middle-income
countries seek to address the needs of large cohorts of
PLHIV who are taking antiretroviral drugs on a lifelong
basis. Introducing and pursuing a ‘fourth 90’ target to
address the challenges facing virally suppressed PLHIV
in high-income countries will thus set an important pre-
cedent for other countries to follow.
Another consideration is late diagnosis of HIV, which
remains a major problem in countries at all income
levels [9]. Research suggests that, even after achieving
viral suppression, people who commenced antiretro-
viral therapy with severely weakened immune systems
are vulnerable to a range of HIV- and non-HIV-
specific diseases [10–12]. The ideal, of course, would
be to eliminate late diagnosis. However, many health
systems worldwide continue to grapple with the ques-
tion of how to incentivize HIV testing even enough to
achieve the ‘first 90’ target of diagnosing 90 % of HIV-
Fig. 1 The ‘fourth 90’: proposed revision to the UNAIDS 90-90-90 targets*
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positive people [13]. While work on this front continues,
increasing our understanding of the health needs of virally
suppressed PLHIV, including those diagnosed late, will
yield clinical and operational guidance that will be of im-
mense value in virtually all healthcare settings worldwide.
Our final reason for urging suitably positioned countries
to rise to the challenge of exploring what is needed for
PLHIV “beyond viral suppression” relates to the changing
dynamics of health systems. In recent years, health systems
experts have begun calling for health services and other
health system elements to be centered on the needs of indi-
viduals and communities, which would be a departure from
the disease-specific orientation that currently characterizes
many aspects of health systems worldwide. However, there
is not yet a clear consensus about what ‘people-centered
health systems’ should look like in practice [14]. This issue
has emerged at a time when health systems in some low-
and middle-income countries are being severely strained by
the rising incidence in various NCDs [15].
Conclusions
We believe that health systems everywhere need to be-
come more integrated and people-centered to success-
fully meet the needs of virally suppressed PLHIV.
Importantly, by doing so, these systems can better meet
the needs of all of their constituents, regardless of HIV
status, in an era when many populations worldwide are
living much longer with multiple comorbidities. It is im-
perative for the global community to approach health-
related well-being holistically from this perspective. We
therefore challenge our colleagues working on HIV
worldwide to take up the ‘fourth 90’ – ensure that 90 %
Fig. 3 Expanding the HIV continuum of care cascade: an example using data from Switzerland*
Fig. 2 Expanding the HIV continuum of care cascade: an example using data from Vietnam*
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of people with viral load suppression have good health-
related quality of life – as a central guiding objective in
the next stage of the march to end HIV.
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